Published on 22/12/2025
Transparency in UK Clinical Trials After Brexit: Regulatory Shifts and Practical Realities
Transparency in clinical trials is central to building public trust, ensuring ethical compliance, and maintaining scientific credibility. In the European Union, the EU Clinical Trials Regulation (CTR) 536/2014 established strong requirements for publication of trial protocols and results through the Clinical Trials Information System (CTIS). Following Brexit, the United Kingdom (UK) has developed its own framework, which aligns with some EU principles but diverges in implementation.
Post-Brexit, UK sponsors must navigate a new landscape: MHRA guidance, Health Research Authority (HRA) requirements, and national registers such as ISRCTN. This article provides a critical commentary on how transparency obligations are evolving in the UK, the challenges sponsors face, and the potential long-term implications for global clinical development.
Background and Regulatory Framework
HRA Transparency Requirements
The HRA requires sponsors to register all clinical trials in a publicly accessible registry before enrolment begins. Results must be made publicly available within 12 months of trial completion, with penalties for non-compliance introduced in recent reforms.
MHRA Post-Brexit Guidance
MHRA maintains oversight of transparency obligations linked to Clinical Trial Authorisations (CTAs). Unlike EU CTIS, the UK currently relies on registries such as ISRCTN and EU Clinical
Global Harmonisation Challenges
UK divergence from EU systems poses challenges for multinational studies, requiring sponsors to duplicate registry entries and adapt to parallel reporting timelines.
Commentary on Key Transparency Challenges
Challenge 1 — Multiple Registries and Fragmentation
Post-Brexit, UK trials may need registration in ISRCTN, EU CTR (for EU sites), and potentially ClinicalTrials.gov for global compliance. This creates administrative duplication.
Commentary: Consolidation into a UK national portal could reduce burden, but until then, sponsors must invest in registry compliance teams.
Challenge 2 — Enforcement of Disclosure Rules
HRA audits reveal that a significant proportion of academic and NHS-sponsored trials fail to publish results on time.
Commentary: Stricter enforcement, including potential funding penalties, will likely improve compliance but may strain under-resourced NHS Trusts.
Challenge 3 — Balancing Transparency with Confidentiality
Sponsors express concerns about disclosing commercially sensitive information in early-stage trials.
Commentary: UK regulators emphasise patient safety and ethical obligations over commercial concerns, but guidance on redaction remains less prescriptive than the EU CTR.
Challenge 4 — Patient and Public Involvement
Transparency is not just about data—it involves communicating results in plain language summaries.
Commentary: The UK framework prioritises lay summaries, aligning with international trends, but challenges remain in standardising language for diverse populations.
Best Practices for Sponsors and Investigators
- Register trials prospectively on ISRCTN or other recognised registries.
- Plan for timely results publication (within 12 months of completion).
- Engage patients and the public in designing plain language summaries.
- Maintain version-controlled records in the Trial Master File (TMF) to demonstrate compliance.
- Audit registry compliance as part of trial governance processes.
Scientific and Regulatory Evidence
- Medicines for Human Use (Clinical Trials) Regulations 2004 (as amended)
- HRA Transparency Strategy and Annual Reports
- MHRA Post-Brexit Guidance Documents
- ICH E6(R2) – Good Clinical Practice
- WHO ICTRP Registry Criteria
Special Considerations
- Oncology Trials: Transparency is critical for safety signal detection across global programmes.
- Pediatrics: Lay summaries for parents and children require tailored formats.
- Rare Diseases: Publication of small dataset trials raises confidentiality risks for participants.
- Decentralised Trials: Transparency of digital endpoints and patient-reported outcomes is a growing focus for regulators.
When Sponsors Should Seek Regulatory Advice
- If unsure about dual registration requirements for UK-EU trials.
- When publishing sensitive biomarker or genetic data.
- If academic sponsors lack resources for timely compliance.
- For first-in-human studies requiring confidentiality safeguards.
FAQs
1. What is the UK’s main clinical trial registry post-Brexit?
ISRCTN is commonly used, though legacy trials may remain in EUCTR. A UK-specific portal is under development.
2. How quickly must results be disclosed?
Within 12 months of trial completion, as required by HRA and MHRA guidance.
3. Are plain language summaries required in the UK?
Yes, HRA mandates lay summaries for patient and public communication.
4. Does Brexit change EUCTR obligations?
Yes. UK-only trials no longer use CTIS, but EU trials including UK sites must comply with both EU and UK rules.
5. What happens if sponsors fail to publish results?
Non-compliance may lead to HRA audits, reputational damage, or funding penalties for academic sponsors.
6. Do CROs play a role in transparency compliance?
Yes, CROs often manage registry entries and ensure documentation is uploaded to TMFs.
7. How does transparency support public trust?
By ensuring participants and the public see results, reinforcing the ethical justification for trial participation.
Conclusion
UK clinical trial transparency obligations post-Brexit are evolving toward a more independent system, while still aligned with global expectations. Sponsors must manage fragmented registry requirements, stricter enforcement by HRA, and the need for plain language communication. Early planning, strong CRO support, and proactive dialogue with regulators are essential to maintain compliance and public confidence in the UK research environment.